Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) reached a new 52-week low during trading on Wednesday after SunTrust Banks lowered their price target on the stock to $18.00. SunTrust Banks currently has a buy rating on the stock. Bellicum Pharmaceuticals traded as low as $5.78 and last traded at $5.76, with a volume of 5270746 shares. The stock had previously closed at $8.20.
A number of other brokerages have also recently commented on BLCM. Zacks Investment Research raised Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. BidaskClub raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 4th. ValuEngine raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. Raymond James Financial reissued a “buy” rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, December 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $10.00 price objective (down previously from $12.00) on shares of Bellicum Pharmaceuticals in a research note on Wednesday. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $15.43.
In other news, CFO Alan A. Musso sold 6,206 shares of the firm’s stock in a transaction that occurred on Monday, November 27th. The stock was sold at an average price of $9.89, for a total value of $61,377.34. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Bros. Advisors Lp Baker sold 880,735 shares of the firm’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $8.20, for a total value of $7,222,027.00. The disclosure for this sale can be found here. Insiders sold 1,165,145 shares of company stock worth $9,696,662 in the last 90 days. Corporate insiders own 18.77% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Bellicum Pharmaceuticals by 13.6% in the second quarter. Vanguard Group Inc. now owns 1,206,436 shares of the biopharmaceutical company’s stock valued at $14,092,000 after purchasing an additional 144,854 shares in the last quarter. State Street Corp lifted its holdings in shares of Bellicum Pharmaceuticals by 16.6% in the second quarter. State Street Corp now owns 416,966 shares of the biopharmaceutical company’s stock valued at $4,872,000 after purchasing an additional 59,321 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Bellicum Pharmaceuticals in the third quarter valued at approximately $4,723,000. Northern Trust Corp lifted its holdings in shares of Bellicum Pharmaceuticals by 29.5% in the second quarter. Northern Trust Corp now owns 341,555 shares of the biopharmaceutical company’s stock valued at $3,989,000 after purchasing an additional 77,760 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in Bellicum Pharmaceuticals by 223.5% during the second quarter. Goldman Sachs Group Inc. now owns 138,000 shares of the biopharmaceutical company’s stock worth $1,612,000 after acquiring an additional 95,336 shares during the period. Institutional investors own 55.24% of the company’s stock.
The stock has a market capitalization of $202.02, a price-to-earnings ratio of -2.03 and a beta of 1.18. The company has a quick ratio of 6.08, a current ratio of 6.08 and a debt-to-equity ratio of 0.23.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.03. The business had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.03 million. The business’s revenue was up 18.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.66) earnings per share. sell-side analysts forecast that Bellicum Pharmaceuticals Inc will post -2.93 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Bellicum Pharmaceuticals (BLCM) Hits New 52-Week Low Following Analyst Downgrade” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/01/bellicum-pharmaceuticals-blcm-hits-new-52-week-low-following-analyst-downgrade.html.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.